In vivo effects of GPER agonists and antagonists are complicated by the widespread expression of GPER beyond tumor cells, including in tumor-associated immune and stromal cells (such as fibroblasts, adipocytes, and vascular cells). The gene discussed is GPER1; the disease is neoplasm.